Table 2.

Baseline characteristics of FACT participants with PTHM measures at baseline in 400 μg folic acid and placebo groups

400 μg FA (n = 107)Placebo (n = 60)
CharacteristicMedian (IQR)Median (IQR)Pa
Age, y38 (34–46)38 (33–44)0.29
BMI,b kg/m219.3 (17.8–21.0)19.5 (18.1–22.1)0.37
RBC folate,c nmol/L424 (360–617)472 (357–548)0.74
Plasma folate, nmol/L13 (8–19)13 (10–17)0.53
Plasma vitamin B12, pmol/L213 (154–296)220 (150–323)0.76
Plasma choline, μmol/L11.0 (9.9–13.0)10.9 (9.7–13.1)0.86
Plasma betaine, μmol/L42.4 (35.1–51.9)43.4 (34.1–54.7)0.84
Plasma Hcys, μmol/L11.4 (8.6–15.5)11.7 (8.9–16.0)0.77
Blood arsenic, μg/L8.4 (6.0–12.7)8.7 (6.1–11.5)0.83
bSe, μg/L135 (122–152)136 (124–150)0.93
uCr, mg/dL46 (32–83)40 (20–62)0.03
H3K36me2,d relative % of total H31.48 (1.28–1.86)1.56 (1.37–1.73)0.61
H3K36me3,e relative % of total H31.62 (1.21–2.07)1.67 (1.38–2.00)0.51
H3K79me2,f relative % of total H31.20 (1.06–1.68)1.16 (0.96–1.59)0.18
Folate deficient,g %26.218.30.25
Vitamin B12 deficient,h %23.426.70.63
HHcys,i %39.346.70.35
Ever smoked cigarette, %50.551.70.88
Ever used betel nut,j %28.631.70.68
Education > 5 y, %22.416.70.37
Own TV, %42.140.00.80
  • Abbreviations: HCys, homocysteine; HHCys, hyperhomocysteinemia; IQR, interquartile range.

  • aP was from Wilcoxon rank-sum test and χ2 test for difference between 400 μg folic acid and placebo groups for continuous and categorical variables, respectively.

  • bn = 104 for 400 μg folic acid, n = 59 for placebo group.

  • cn = 103 for 400 μg folic acid group.

  • dn = 105 for 400 μg folic acid, n = 56 for placebo group.

  • en = 102 for 400 μg folic acid, n = 57 for placebo group.

  • fn = 106 for 400 μg folic acid, n = 60 for placebo group.

  • gPlasma folate < 9 nmol/L.

  • hPlasma vitamin B12 < 151 pmol/L.

  • iPlasma Hcys > 13 μmol/L.

  • jn = 104 for 400 μg folic acid.